Janssen Y J, Deurenberg P, Roelfsema F
Department of Endocrinology, Leiden University Hospital, The Netherlands.
J Clin Endocrinol Metab. 1997 Oct;82(10):3349-55. doi: 10.1210/jcem.82.10.4272.
Due to the use of various, and mostly indirect, methods to estimate total body water (TBW) and extracellular water (ECW), there is no agreement about whether body water distribution, i.e. the ECW to TBW ratio, is normal in GH-deficient (GHD) subjects at baseline and during recombinant human GH (rhGH) treatment. We studied body water distribution in 14 patients with adult-onset GHD and in 28 healthy controls. We also investigated the effect of GH replacement therapy for 4 and 52 weeks on body water distribution. All patients started with a dose of 0.6 IU rhGH/day for the first 4 weeks. After 52 weeks, the dose varied between 0.6-1.8 IU/day. TBW and ECW were measured by dilution of deuterium and bromide, respectively. Both parameters were also estimated using multifrequency bioelectrical impedance (BIA). Patients with GHD had significantly lower ECW and TBW than healthy controls. In addition, the ECW to TBW ratio was significantly lower in GHD patients than in healthy controls. Four weeks of GH treatment significantly increased body weight, TBW, ECW, and ECW/TBW. A further increase in TBW, but not ECW, was found after 52 weeks of treatment. The mean increases in TBW and ECW from the baselines were 2.5 +/- 0.3 and 2.0 +/- 0.3 L, respectively. The correlation coefficient and the estimated reliability between measured and estimated TBW and ECW at any time point were all high (> 0.91 and > 0.95, respectively). In general, both ECW and TBW were overestimated by multifrequency BIA in GHD adults. During treatment, the overestimation of both ECW and TBW diminished. The estimation error was correlated with the level of the body water compartment and the ratio of ECW to TBW. The estimated change in ECW with rhGH treatment was underestimated by multifrequency BIA. We conclude that GHD adults have lower ECW and TBW and a lower ECW to TBW ratio, as measured by dilution techniques. The ECW to TBW ratio can be normalized within 4 weeks of rhGH treatment at a dose of 0.6 IU/day. Finally, we conclude that multifrequency impedance measurements do not give valid estimates of body water compartments in the follow-up of patients with GHD.
由于使用了各种(大多为间接的)方法来估计总体水(TBW)和细胞外水(ECW),对于生长激素缺乏(GHD)患者在基线期及重组人生长激素(rhGH)治疗期间的身体水分分布,即ECW与TBW的比值是否正常,目前尚无定论。我们研究了14例成年起病的GHD患者和28例健康对照者的身体水分分布情况。我们还调查了4周和52周的生长激素替代治疗对身体水分分布的影响。所有患者在开始的4周内每天使用0.6 IU的rhGH。52周后,剂量在0.6 - 1.8 IU/天之间变化。分别通过氘和溴化物稀释法测量TBW和ECW。这两个参数也使用多频生物电阻抗(BIA)进行估计。GHD患者的ECW和TBW显著低于健康对照者。此外,GHD患者的ECW与TBW比值显著低于健康对照者。4周的生长激素治疗使体重、TBW、ECW和ECW/TBW显著增加。治疗52周后发现TBW进一步增加,但ECW未增加。TBW和ECW相对于基线的平均增加量分别为2.5±0.3和2.0±0.3 L。在任何时间点,测量的和估计的TBW及ECW之间的相关系数和估计可靠性都很高(分别>0.91和>0.95)。总体而言,多频BIA在GHD成年人中高估了ECW和TBW。在治疗期间,对ECW和TBW的高估有所减少。估计误差与身体水分隔室水平以及ECW与TBW的比值相关。多频BIA低估了rhGH治疗后ECW的估计变化。我们得出结论,通过稀释技术测量,GHD成年人的ECW和TBW较低,且ECW与TBW比值较低。以0.6 IU/天的剂量进行rhGH治疗4周内,ECW与TBW比值可恢复正常。最后,我们得出结论,在GHD患者的随访中,多频阻抗测量无法有效估计身体水分隔室。